You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The $302 million deal, which was expected to close by the end of the year, passed US government antitrust review in August.
Last week, the G-BA, a committee that decides about reimbursable medical services in Germany, said it will start a methods evaluation of noninvasive prenatal testing.
Sequenom, which will be acquired by LabCorp this year, saw an increase in testing for average-risk pregnancies in the quarter, despite lower overall revenues.
The company said it planned to launch version 3 of Panorama this year during a conference call discussing its second quarter 2016 performance.
Test volume growth for its Panorama NIPT and Horizon carrier screening tests drove its revenues gains year over year.
LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
Unilabs has licensed the rights to develop, validate, and run Natera's Panorama NIPT technology out of its own laboratories.
Based on data from more than 6,000 clinical cases, the investigators from Switzerland advocated for an expansion of NIPT to cover additional alterations and associated phenotypes.
Although Sequenom had garnered support from a diverse range of groups who wanted clarity on patent eligibility, the Supreme Court denied the petition.
Genomed, based in Warsaw, offers sequencing-based diagnostic and research services and brought BGI's noninvasive prenatal NIFTY test in house last year.